🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A novel cathepsin G (CG1/HLA-A2)-targeting, CAR-T cell (CG1/A2xCD3) demonstrates selective pre-clinical activity against HLA-A2+ AML #bmtsm #leusm #CARTcell MD Anderson Cancer Center #Gheatalatrash Leukemia Journal nature.com/articles/s4137…

Join us for this free virtual highlights of #MDSsm abstracts from #ASCO2025 & #EHA2025 on July 1st, 2025 9am-11am eastern USA time delivered by the authors themselves and debated by an expert panel VJHemOnc register for free at vjhemonc.com/event/post-eha…

How I treat secondary acute myeloid leukemia ashpublications.org/blood/article-… #leusm #AML

This is a really important paper - immunogenic tumour associated antigens seem to be more associated with aberrantly expressed extragenic RNA than the classical mutations nature.com/articles/s4301…

Sledgehammer to hit nut or actually clinically and more cost-effective in Ph+ #ALL? As usual, need a phase 3 Dr francesca kinsella Lindsay George Bernard Maybury Sridhar Chaganti UHBMyeloid

Go Charlie Craddock CBE !

Finally out.. 3rd edition of #COVID guidance by ECIL-10👇🏻🙏 Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy The EBMT BSH - Haematology BSBM CDC European Hematology Association nature.com/articles/s4137…

#EHA2025 #youngEHA Great presentation by Dr. DiNardo, how to improve on VEN+HMA for intensive ineligible AML pts.. 1. Ven resistance mechanisms. 2. Novel targets 3. Ven triplets under development #leusm #AML #venetoclax_4_AML

Exciting times for mutCALR MPNs - lovely data from the ET cohort presented in late breaking abstract at European Hematology Association. Rapid platelet control after just 2 doses with 89% of patients benefitting from a molecular response with INCA033989. MPN Voice MPN_Hub MPN Research Foundation

Triple Threat: Revumenib Combo Delivers Powerful Punch in High-Risk AML published in Journal of Clinical Oncology Summary: In older adults newly diagnosed with AML harboring NPM1 mutations or KMT2A rearrangements, a phase I trial of azacitidine, venetoclax, and the menin inhibitor revumenib

Triplet Triumph: IDH-Targeted Combo Shows High Remission in Tough-to-Treat AML Summary: For newly diagnosed, intensive chemo–ineligible AML patients with IDH mutations, a triplet regimen of a hypomethylating agent (AZA or oral decitabine), venetoclax, and an IDH inhibitor

Macrophage Makeover: Bexmarilimab Boosts Azacitidine in High-Risk MDS and AML Summary: In a phase 1 trial, the Clever-1–blocking antibody bexmarilimab, combined with azacitidine, showed a manageable safety profile and encouraging clinical activity in patients with high-risk

With the disappointing announcement today by AbbVie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML | Journal of Clinical Oncology ascopubs.org/doi/full/10.12… 1.

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML | Journal of Clinical Oncology ascopubs.org/doi/full/10.12… Congratulations to Dr. Zeidner and BeatAML team. 1. Revumenib was given continuously, dose adjusted for CYP3A4i 2. Ven for 28

Almost half of patients with acute myeloid leukemia are aged ≥70 years at diagnosis. ow.ly/Glpg50WahLs #BloodSpotlight #myeloidneoplasia #transplantation

Despite increased use of next-generation sequencing, newly diagnosed patients considering intensive chemotherapy still benefit from FLT3 polymerase chain reaction testing to facilitate TKI initiation during induction. ow.ly/kz9Q50WahTY #BloodSpotlight

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera | Leukemia nature.com/articles/s4137…

Not nearly so straightforward as #myeloid diseases Sridhar Chaganti Lindsay George UHBMyeloid